Johnson & Johnson, tiny RNA biotech Arcturus combine for hepatitis B work
fiercebiotech | October 19, 2017
A little over a month after Johnson & Johnson pulled the plug on its hepatitis C pipeline and said it would focus on hepatitis B, the Big Pharma’s biotech unit has notched a deal with Arcturus Therapeutics to help it do exactly that.